CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has met its second milestone in its option agreement with the Novartis Option Fund and will move on to the next phase to validate targets for inflammatory bowel disease (IBD) using Cequent's proprietary TransKingdom RNA interference [tkRNAi(TM)] technology in animal models. Specific payment terms and targets were not disclosed.
"IBD is actually a spectrum of diseases, and the power of RNAi is that you could potentially design therapeutics specifically to target the individual forms of the disease," said Cequent President and CEO, Peter Parker. "When we started the Novartis program, we were evaluating eight targets simultaneously as potential therapeutics for inflammatory bowel disease. Our milestone goal, which we accomplished, was to winnow the targets down to three that we will further validate in in vivo animal trials before Cequent selects the single target to be the subject of the Option agreement. We believe our success with this work, along with progress in our other development programs for Familial Polyposis (FAP) and Human Papilloma Virus (HPV), demonstrate the potential of our tkRNAi technology to become an important tool to better understand, and ultimately, to treat many devastating diseases."
Said Steven Tregay, PhD, a managing director of Novartis Option Fund,
"We are impressed with both the quality and speed of the work that Cequent
is doing on the IBD program -- as well as the potential of their tkRNAi
platform. Creating compounds to address eight targets and completing in
vitro screening in only nine months would have been virtually impossible
with traditional small-molecule-based drug discovery technologies. We're
pleased to release the milestone payment to Cequent, and look forward to
our continued relationship both as venture
|SOURCE Cequent Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved